A Kim, K Mo, H Kwon, S Choe, M Park, W Kwak… - Epigenomes, 2023 - mdpi.com
Breast cancer remains a common cause of cancer-related death in women. Therefore, further studies are necessary for the comprehension of breast cancer and the revolution of …
NA Selem, H Nafae, T Manie, RA Youness… - Pathology-Research and …, 2023 - Elsevier
Background Triple negative breast cancer (TNBC) is an immunogenically hot tumor. The immune checkpoint blockades (ICBs) have been recently emerged as promising therapeutic …
I Khurram, MU Khan, S Ibrahim, A Saleem, Z Khan… - Scientific Reports, 2023 - nature.com
Breast cancer is the most prevalent and leading cause of mortality worldwide among women. Cell-free DNA (cfDNA) analysis is an alternative quantitative approach to …
Epigenetic modifications are heritable yet reversible, essential for normal physiological functions and biological development. Aberrant epigenetic modifications, including DNA …
P Mondal, SM Meeran - Frontiers in Pharmacology, 2023 - frontiersin.org
Platinum-based drugs are the first line of therapeutics against many cancers, including lung cancer. Lung cancer is one of the leading causes of cancer-related death worldwide …
P Mondal, SM Meeran - Cancer and Metastasis Reviews, 2024 - Springer
Resistance to therapeutic agents is one of the major challenges in cancer therapy. Generally, the focus is given to the genetic driver, especially the genetic mutation behind the …
Aims Tamoxifen (TAM) selectively modulates estrogen receptors and is widely used in breast cancer treatment. However, resistance to this drug appears in 40% of estrogen …
In recent decades, various investigations have indicated that natural compounds have great potential in the prevention and treatment of different chronic disorders including different …
C Suri, S Swarnkar, L Bhaskar, HK Verma - Non-coding RNA, 2024 - mdpi.com
Introduction: Lung cancer remains one of the most prevalent and deadly cancers globally, with high mortality rates largely due to late-stage diagnosis, aggressive progression, and …